Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Klaus Seibel is active.

Publication


Featured researches published by Klaus Seibel.


Atherosclerosis | 1987

Circadian variation of the hypocholesterolemic effect of K13.004 in rats

Michael Schliack; Roland Löser; Klaus Seibel

The hypocholesterolemic effect in rats of the new lipid-lowering agent K13.004 was dependent on the time of day of its application. This dependence was shifted together with the time of peak activity of hepatic cholesterol synthesis (CS) when the feeding time of the animals was changed. This compound considerably reduced serum cholesterol only if given before the peak of hepatic CS, whereas application afterwards was ineffective. Our finding suggests that this hypolipidemic compound lowers serum cholesterol by inhibition of hepatic CS. Drugs acting in such a way should be administered prior to the maximum of hepatic sterol synthesis.


Archive | 1998

Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt


Archive | 2000

Piperadinyl-substituted pyridylalkane, alkene and alkine carboxamides

Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt; Katja Wosikowski; Isabel Schemainda


Archive | 1997

Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives

Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt


Archive | 2000

Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy

Elfi Biedermann; Rolf Eisenburger; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Isabel Schemainda; Michael Schulz; Klaus Seibel; Klaus Vogt; Katja Wosikowski


Archive | 1997

Pyridyl alkane acid amides as cytostatics and immunosuppressives

Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt


Archive | 1998

Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic and immunosuppressive agents

Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt; Katja Wosikowski


Archive | 1998

Piperidinyl-substituted pyridylalkane, alkene and alkine carboxamides as cytostatics and immunesuppressants

Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt; Katja Wosikowski


Archive | 1996

Use by inhalation of antidepressants for the treatment of asthma

Rolf Eisenburger; Josef Maximilian Dr Hofer; Peter Jank; Arnim Laicher; Klaus Seibel; Friedrich Stanislaus


Archive | 2000

Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents

Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt; Katia Wosikowski; Isabel Schemainda

Collaboration


Dive into the Klaus Seibel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Katja Wosikowski

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge